Why Choosing the Right CPET Trays Manufacturer Matters for Your Food Business
CPET (Crystallized Polyethylene Terephthalate) trays are the invisible backbone of modern food safety and sustainability. From freezer-to-oven convenience to reducing plastic waste, these trays protect meals for millions daily. But not all manufacturers deliver equal quality. Choosing the right CPET trays manufacturer impacts your product safety, operational costs, and environmental footprint. FDA/EC Compliance: Non-negotiable for direct food contact
ISO 9001 & 22000: Proof of consistent quality management
BPA-Free Guarantees: Third-party tested material safety reports Feature Why It Matters -40°C to 220°C Tolerance Survives blast freezing + convection ovens Oxygen Barrier (<0.5 cc/m²/day) Extends shelf life by 30-50% Moisture Resistance (<0.7 g/m²/day) Prevents sogginess in saucy foods
*Example: JH Packaging's dual-oven trays withstand 45-minute cook cycles without warping.* Compartmentalization: 2-5 section trays for meal kits
Embossing/Texturing: Brand logos + anti-slip surfaces
Denesting Angles: Critical for high-speed filling lines
(Need custom CPET tray solutions? Explore our design studio) 80% PCR Content: Using Faerch's EVOLVE technology to reduce virgin plastic
100% Recyclability: Trays return as new trays via circular partnerships
Energy Recovery: 40% lower carbon footprint vs. competitors
*We're advancing toward Faerch's 100,000-ton PCR target through our sustainable manufacturing practices.* ±0.15mm thickness uniformity
Automated optical defect detection
<2% denesting failure rate in production
Case Study: Woolworths' 28-Year Partnership Problem: Frequent tray failure in frozen meal lines
Solution: Custom oval trays with reinforced corners
Results: Zero recalls since 1996 12% lighter trays = $380K/year shipping savings 100% retailer microwave-safety compliance
Spec Comparison Table Tray Type Max Stack Height Load Capacity Thermal Shock Resistance Standard CPET 2.2m 1.8kg 3 cycles JH Reinforced 3.5m 3.0kg 25+ cycles Aluminum 1.8m 2.5kg Unlimited Bagasse 1.5m 1.2kg 0 cycles Material CO2 Emissions Water Usage Recycled Content CPET (JH) 420kg 9,000L 50-80% PP Plastic 780kg 14,500L 5-15% PLA 'Bioplastic' 650kg 22,000L 0%
*Key Fact: Switching to our trays cuts landfill waste by 73% vs. multi-layer packaging.* Tray-to-Tray Recycling: Used trays become new food containers PCR Sourcing: Partnering with ocean plastic recovery programs Energy Recovery: Non-recyclable waste powers manufacturing
Q: How do I verify a manufacturer's quality claims?
A: Demand third-party lab reports for: Migration testing (EU 10/2011 standards)
50-cycle thermal shock documentation
Certificates of Analysis for PCR content
Q: Can CPET trays be recycled locally?
A: Yes – they're #1 PET plastic. Over 85% of U.S. curbside programs accept them when clean. JH provides recycling guidance labels for consumers.
Choosing your CPET trays manufacturer isn't just a procurement decision – it's a commitment to food safety, efficiency, and planetary health. JH Packaging combines 30+ years of engineering expertise with radical sustainability.
Ready to upgrade your packaging?
➤ Request Custom Tray Samples
➤ Explore Our Sustainability Report
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J., June 05, 2025--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. "FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too," said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. "For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance." "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients," said Nicole Jacque, co-founder of FIP Global Cats. "Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP." Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About WedgewoodWedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit View source version on Contacts Jennifer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J.--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment." Share GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. 'FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,' said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. 'For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.' "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,' said Nicole Jacque, co-founder of FIP Global Cats. 'Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.' Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About Wedgewood Wedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit
Business Wire
an hour ago
- Business Wire
URGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP UroGen class action lawsuit. Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen as well as certain of UroGen's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the UroGen class action lawsuit, please provide your information here: CASE ALLEGATIONS: UroGen engages in the development and commercialization of solutions for specialty cancers. According to the complaint, UroGen's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. The UroGen class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved. The UroGen class action lawsuit further alleges that on May 16, 2025, the FDA published a briefing document in advance of its Oncologic Drugs Advisory Committee meeting regarding UroGen's NDA for UGN-102, which stated that '[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret,' and that the FDA had 'recommended a randomized trial design to the Applicant several times during their product's development due to concerns with interpreting efficacy results' but UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock fell nearly 26%, according to the complaint. Then, on May 21, 2025, the UroGen class action lawsuit further alleges that the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk of the investigation therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock fell nearly 45%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired UroGen securities during the Class Period to seek appointment as lead plaintiff in the UroGen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the UroGen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the UroGen class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the UroGen class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
